Docking Simulations of G-Protein Coupled Receptors Uncover Crossover Binding Patterns of Diverse Ligands to Angiotensin, Alpha-Adrenergic and Opioid Receptors: Implications for Cardiovascular Disease and Addiction

Recent bioassay studies have unexpectedly supported the high (computationally predicted) binding affinities of angiotensin receptor blockers (ARBs) at α-adrenergic receptors (αARs) in isolated smooth muscle. Computational predictions from ligand docking studies are consistent with very low concentra...

Full description

Saved in:
Bibliographic Details
Main Authors: Harry Ridgway, Graham J. Moore, Laura Kate Gadanec, John M. Matsoukas
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Biomolecules
Subjects:
Online Access:https://www.mdpi.com/2218-273X/15/6/855
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849433397098708992
author Harry Ridgway
Graham J. Moore
Laura Kate Gadanec
John M. Matsoukas
author_facet Harry Ridgway
Graham J. Moore
Laura Kate Gadanec
John M. Matsoukas
author_sort Harry Ridgway
collection DOAJ
description Recent bioassay studies have unexpectedly supported the high (computationally predicted) binding affinities of angiotensin receptor blockers (ARBs) at α-adrenergic receptors (αARs) in isolated smooth muscle. Computational predictions from ligand docking studies are consistent with very low concentrations of ARBs (e.g., sartans or bisartans) that partially reduce (20–50%) the contractile response to phenylephrine, suggesting that some ARBs may function as partial inverse agonists at αARs. Virtual ligand screening (docking) and molecular dynamics (MD) simulations were carried out to explore the binding affinities and stabilities of selected non-peptide ligands (e.g., ARBs and small-molecule opioids) for several G-protein coupled receptor (GPCR) types, including angiotensin II (AngII) type 1 receptor (AT<sub>1</sub>R), α1AR, α2AR, and μ-(µOR) and ժ-opioid receptors (ժOR). Results: All ligands docked preferentially to the binding pocket on the cell surface domain of the GPCR types investigated. Drug binding was characterized by weak interactions (hydrophobic, hydrogen bonding, pi-pi) and stronger ionic and salt-bridge interactions (cation-pi and cation-anion interactions). Ligands specific to each GPCR category showed considerable cross-binding with alternative GPCRs, with small-molecule medications appearing less selective than their peptide or ARB functional equivalents. ARBs that exhibit higher affinities for AT<sub>1</sub>R also demonstrate higher affinities for µORs and ժORs than opiate ligands, such as fentanyl and naltrexone. Moreover, ARBs had a higher affinity for αARs than either alpha agonists (epinephrine and phenylephrine) or inhibitors (prazosin and doxazosin). MD simulations of membrane-embedded ARB-GPCR complexes proved stable over nanosecond time scales and suggested that some ARBs may behave as agonists or antagonists depending on the GPCR type. Based on the results presented in this and related investigations, we propose that agonists bind to the resting A-site of GPCRs, while inverse agonists occupy the desensitizing D-site, which partial agonists like morphine and fentanyl share, contributing to addiction. ARBs block both AngII and alpha receptors, suggesting that they are more potent antihypertensive drugs than ACE inhibitors. ARBs have the potential to inhibit morphine tolerance and appear to disrupt receptor desensitization processes, potentially by competing at the D-site. Our results suggest the possible therapeutic potential of ARBs in treating methamphetamine and opiate addictions.
format Article
id doaj-art-c7cfa0af149c47d186824b8a6fe0c6bf
institution Kabale University
issn 2218-273X
language English
publishDate 2025-06-01
publisher MDPI AG
record_format Article
series Biomolecules
spelling doaj-art-c7cfa0af149c47d186824b8a6fe0c6bf2025-08-20T03:27:05ZengMDPI AGBiomolecules2218-273X2025-06-0115685510.3390/biom15060855Docking Simulations of G-Protein Coupled Receptors Uncover Crossover Binding Patterns of Diverse Ligands to Angiotensin, Alpha-Adrenergic and Opioid Receptors: Implications for Cardiovascular Disease and AddictionHarry Ridgway0Graham J. Moore1Laura Kate Gadanec2John M. Matsoukas3Institute for Sustainable Industries and Liveable Cities, Victoria University, Melbourne, VIC 8001, AustraliaPepmetics Inc., 772 Murphy Place, Victoria, BC V8Y 3H4, CanadaImmunology and Translational Research Group, Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, AustraliaImmunology and Translational Research Group, Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, AustraliaRecent bioassay studies have unexpectedly supported the high (computationally predicted) binding affinities of angiotensin receptor blockers (ARBs) at α-adrenergic receptors (αARs) in isolated smooth muscle. Computational predictions from ligand docking studies are consistent with very low concentrations of ARBs (e.g., sartans or bisartans) that partially reduce (20–50%) the contractile response to phenylephrine, suggesting that some ARBs may function as partial inverse agonists at αARs. Virtual ligand screening (docking) and molecular dynamics (MD) simulations were carried out to explore the binding affinities and stabilities of selected non-peptide ligands (e.g., ARBs and small-molecule opioids) for several G-protein coupled receptor (GPCR) types, including angiotensin II (AngII) type 1 receptor (AT<sub>1</sub>R), α1AR, α2AR, and μ-(µOR) and ժ-opioid receptors (ժOR). Results: All ligands docked preferentially to the binding pocket on the cell surface domain of the GPCR types investigated. Drug binding was characterized by weak interactions (hydrophobic, hydrogen bonding, pi-pi) and stronger ionic and salt-bridge interactions (cation-pi and cation-anion interactions). Ligands specific to each GPCR category showed considerable cross-binding with alternative GPCRs, with small-molecule medications appearing less selective than their peptide or ARB functional equivalents. ARBs that exhibit higher affinities for AT<sub>1</sub>R also demonstrate higher affinities for µORs and ժORs than opiate ligands, such as fentanyl and naltrexone. Moreover, ARBs had a higher affinity for αARs than either alpha agonists (epinephrine and phenylephrine) or inhibitors (prazosin and doxazosin). MD simulations of membrane-embedded ARB-GPCR complexes proved stable over nanosecond time scales and suggested that some ARBs may behave as agonists or antagonists depending on the GPCR type. Based on the results presented in this and related investigations, we propose that agonists bind to the resting A-site of GPCRs, while inverse agonists occupy the desensitizing D-site, which partial agonists like morphine and fentanyl share, contributing to addiction. ARBs block both AngII and alpha receptors, suggesting that they are more potent antihypertensive drugs than ACE inhibitors. ARBs have the potential to inhibit morphine tolerance and appear to disrupt receptor desensitization processes, potentially by competing at the D-site. Our results suggest the possible therapeutic potential of ARBs in treating methamphetamine and opiate addictions.https://www.mdpi.com/2218-273X/15/6/855alpha-adrenergic receptorangiotensin II type 1 receptorangiotensin receptor blockersbisartanscomputer-aided docking simulationsG-protein-coupled receptors
spellingShingle Harry Ridgway
Graham J. Moore
Laura Kate Gadanec
John M. Matsoukas
Docking Simulations of G-Protein Coupled Receptors Uncover Crossover Binding Patterns of Diverse Ligands to Angiotensin, Alpha-Adrenergic and Opioid Receptors: Implications for Cardiovascular Disease and Addiction
Biomolecules
alpha-adrenergic receptor
angiotensin II type 1 receptor
angiotensin receptor blockers
bisartans
computer-aided docking simulations
G-protein-coupled receptors
title Docking Simulations of G-Protein Coupled Receptors Uncover Crossover Binding Patterns of Diverse Ligands to Angiotensin, Alpha-Adrenergic and Opioid Receptors: Implications for Cardiovascular Disease and Addiction
title_full Docking Simulations of G-Protein Coupled Receptors Uncover Crossover Binding Patterns of Diverse Ligands to Angiotensin, Alpha-Adrenergic and Opioid Receptors: Implications for Cardiovascular Disease and Addiction
title_fullStr Docking Simulations of G-Protein Coupled Receptors Uncover Crossover Binding Patterns of Diverse Ligands to Angiotensin, Alpha-Adrenergic and Opioid Receptors: Implications for Cardiovascular Disease and Addiction
title_full_unstemmed Docking Simulations of G-Protein Coupled Receptors Uncover Crossover Binding Patterns of Diverse Ligands to Angiotensin, Alpha-Adrenergic and Opioid Receptors: Implications for Cardiovascular Disease and Addiction
title_short Docking Simulations of G-Protein Coupled Receptors Uncover Crossover Binding Patterns of Diverse Ligands to Angiotensin, Alpha-Adrenergic and Opioid Receptors: Implications for Cardiovascular Disease and Addiction
title_sort docking simulations of g protein coupled receptors uncover crossover binding patterns of diverse ligands to angiotensin alpha adrenergic and opioid receptors implications for cardiovascular disease and addiction
topic alpha-adrenergic receptor
angiotensin II type 1 receptor
angiotensin receptor blockers
bisartans
computer-aided docking simulations
G-protein-coupled receptors
url https://www.mdpi.com/2218-273X/15/6/855
work_keys_str_mv AT harryridgway dockingsimulationsofgproteincoupledreceptorsuncovercrossoverbindingpatternsofdiverseligandstoangiotensinalphaadrenergicandopioidreceptorsimplicationsforcardiovasculardiseaseandaddiction
AT grahamjmoore dockingsimulationsofgproteincoupledreceptorsuncovercrossoverbindingpatternsofdiverseligandstoangiotensinalphaadrenergicandopioidreceptorsimplicationsforcardiovasculardiseaseandaddiction
AT laurakategadanec dockingsimulationsofgproteincoupledreceptorsuncovercrossoverbindingpatternsofdiverseligandstoangiotensinalphaadrenergicandopioidreceptorsimplicationsforcardiovasculardiseaseandaddiction
AT johnmmatsoukas dockingsimulationsofgproteincoupledreceptorsuncovercrossoverbindingpatternsofdiverseligandstoangiotensinalphaadrenergicandopioidreceptorsimplicationsforcardiovasculardiseaseandaddiction